Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025

AYTU BIOPHARMA, INC

Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.
Q4 net revenue $15.1M (+4% YoY); net loss $19.8M vs $4.6M prior year (incl. $18.1M impairment and derivative losses).
ADHD Portfolio net revenue $57.6M (flat YoY); Pediatric Portfolio $8.8M (+20% YoY).
Cash $31.0M at June 30, 2025; 9th consecutive quarter of positive adjusted EBITDA.
EXXUA (gepirone) for MDD launch on track for Q4 2025; entering >$22B US MDD market with novel first-in-class agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.